帕博利珠单抗对晚期食管胃结合部癌疗效及安全性的Meta分析OA
A Meta-analysis of Efficacy and Safety in Pembrolizumab in Advanced Esophagogastric Junction Cancer
目的 本文旨在评估帕博利珠单抗单药及其联合化疗治疗晚期食管胃结合部癌(esophagogastric junction cancer,EGJC)的疗效及安全性.方法 检索 PubMed、Cochrane、Web of Science 和 Embase 等 8 个数据库,按照纳入排除标准,使用EndNote X9 筛选文献,收集相关结局指标,通过RevMan 5.4 软件进行Meta 分析.结果 本分析共纳入 7 项研究,共计 3 085 例患者.Meta 分析结果表明,帕博利珠单抗组与单纯化疗组的无进展生存期(PFS)无显著统计学差异(HR=0.908;95%CI:0.736~1.119;P=0.363).亚组分析显示,在 CPS≥1 的患者中,帕博利珠单抗未带来显著的 PFS 获益(HR=0.991;95%CI:0.747~1.314;P=0.949),且该亚组内异质性较高(I2=84.4%);而在 CPS≥10 的患者中,帕博利珠单抗表现出更长的 PFS(HR=0.63;95%CI:0.491~0.798;P=0.000 2).在总生存期(OS)方面,帕博利珠单抗较单纯化疗能显著延长患者生存时间(HR=0.753;95%CI:0.695~0.816;P<0.000 1).此外,帕博利珠单抗组的客观缓解率(ORR)亦显著优于单纯化疗组(RR=1.255;95%CI:1.141~1.381;P<0.001).安全性分析显示,帕博利珠单抗组免疫相关不良事件发生率更高,包括免疫性肺炎(RR=7.499;95%CI:2.966~18.958;P<0.001)、甲状腺功能减退(RR=6.338;95%CI:2.169~18.519;P=0.001)及甲状腺功能亢进(RR=3.974;95%CI:2.290~6.895;P<0.001).肝炎风险虽有升高趋势,但差异无统计学意义(RR=4.310;95%CI:0.932~19.943;P=0.062).两组白细胞计数降低(RR=0.909;P=0.727)及血小板计数降低(RR=1.112;P=0.440)方面差异均无统计学意义.结论 研究结果表明,与单纯化疗相比,帕博利珠单抗能显著改善患者 OS 和 ORR,且未显著增加骨髓抑制及肝功能异常发生率,但增加了免疫治疗相关肺炎及甲状腺功能异常的发生率.此外,在 PD-L1 CPS≥10 的患者亚组中,观察到帕博利珠单抗的生存获益尤为显著,提示CPS≥10 的患者可能具有更好的临床疗效.
Objective This article aims to evaluate the efficacy and safety of pembrolizumab and pembrolizumab plus chemotherapy in the treatment of advanced Advanced Esophagogastric Junction Cancer.Methods Computerized searches were conducted in multiple databases,includ 8 databases such as PubMed,Cochrane Library,Web of Science,and Embase.Literature was screened using EndNote X9 based on inclusion and exclusion criteria,relevant outcome indicators were collected,and a meta-analysis was performed using RevMan 5.4 software.Results A total of 7 studies involving 3085 patients were included in this Meta-analysis.The results of the meta-analysis showed that there was no statistically significant difference in progression-free survival(PFS)between the pembrolizumab group and the chemotherapy-alone group(HR=0.908;95%CI:0.736~1.119;P=0.363).Subgroup analysis revealed that in patients with CPS≥1,pembrolizumab didn't bring significant PFS benefits(HR=0.991;95%CI:0.747~1.314;P=0.949),and the heterogeneity within this subgroup was high(I2=84.4%).While in patients with CPS≥10,pembrolizumab showed a longer PFS(HR=0.63;95%CI:0.491~0.798;P=0.000 2).In terms of overall survival(OS),pembrolizumab significantly prolonged the survival time of patients compared with chemotherapy alone(HR=0.753;95%CI:0.695~0.816;P<0.000 1).In addition,the objective response rate(ORR)in the pembrolizumab group was also significantly better than that in the chemotherapy-alone group(RR=1.255;95%CI:1.141~1.381;P<0.001).Safety analysis showed that the incidence of immune-related adverse events was higher in the pembrolizumab group,including immune pneumonia(RR=7.499;95%CI:2.966~18.958;P<0.001),hypothyroidism(RR=6.338;95%CI:2.169~18.519;P=0.001),and hyperthyroidism(RR=3.974;95%CI:2.290~6.895;P<0.001).Although there was an increasing trend in the risk of hepatitis,it did not reach statistical significance(RR=4.310;95%CI:0.932~19.943;P=0.062).There were no statistically significant differences between the two groups in terms of decreased white blood cell count(RR=0.909;P=0.727)and decreased platelet count(RR=1.112;P=0.440).Conclusion The study results show that compared with chemotherapy-alone,pembrolizumab significantly prolonged OS and ORR,and doesn't significantly increase the incidence of myelosuppression and abnormal liver function,but increases the incidence of immune-related pneumonia and abnormal thyroid function.In addition,in the subgroup of patients with CPS≥10,the observed survival benefit was particularly significant,suggesting that patients with CPS≥10 may have better clinical efficacy.
王拴;贾瑞诺;王云轩;李慧敏;李纪远
河南科技大学临床医学院,河南科技大学第一附属医院,中国 洛阳,471003河南科技大学临床医学院,河南科技大学第一附属医院,中国 洛阳,471003河南科技大学临床医学院,河南科技大学第一附属医院,中国 洛阳,471003河南科技大学临床医学院,河南科技大学第一附属医院,中国 洛阳,471003河南科技大学临床医学院,河南科技大学第一附属医院,中国 洛阳,471003
医药卫生
帕博利珠单抗晚期食管胃结合部癌疗效安全性Meta分析
pembrolizumabadvanced gastroesophageal junction cancerefficacysafetymeta-analysis
《食管疾病》 2026 (3)
232-240,9
评论